MINANEWS > MINATEC’s newsletter

Number 58: February 2020

The Di@pason project: Avalun scales up

The Di@pason project: Avalun scales up

Avalun is coordinating the Di@pason project, which will test a connected patient care pathway on a cohort of 10,000 patients on blood thinners in six regions across France. Caregivers will test Avalun’s LabPad INR portable lab, which utilizes consumables manufactured at...

Number 57: December 2019

Clinatec’s innovative neuroprosthesis and exoskeleton protected by eighteen patents

Clinatec’s innovative neuroprosthesis and exoskeleton protected by eighteen patents

Clinatec’s Brain-Computer Interface (BCI) project was recently featured in The Lancet Neurology* and has appeared in the media worldwide. This groundbreaking project shows just how powerful the Clinatec model—medical doctors and technology experts working side-by-side under one roof—is at driving innovation.   The...

Number 56: October 2019

BHT2: MINATEC Entreprises exceeds targets

BHT2: MINATEC Entreprises exceeds targets

Construction on the BHT2 building was completed last spring, and startup Prophesee moved its R&D department into a 154 sq. m space at the end of September. Prophesee’s R&D team will be working on the integration of its neuromorphic vision technology into...

Number 55: June 2019

Aledia invests in own R&D facility

Number 54: April 2019

AIDS vaccine: Lipidots® open the door to a novel approach

AIDS vaccine: Lipidots® open the door to a novel approach

Researchers from Leti, CEA Sciences, and INSERM injected Lipidots® (lipid-based nanoparticles) containing the p24 protein of the Human Immunodeficiency Virus (HIV) into an animal model and obtained a robust and complete immune response. Lipidots® were created by Leti and CNRS in...

More information
X